[1]夏佳春,侯磊.PCSK9在动脉粥样硬化性心血管疾病炎性反应
中的作用[J].国际心血管病杂志,2023,01:5-8.
点击复制
PCSK9在动脉粥样硬化性心血管疾病炎性反应
中的作用(PDF)
《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]
- 期数:
- 2023年01期
- 页码:
- 5-8
- 栏目:
- 综述
- 出版日期:
- 2023-01-20
文章信息/Info
- Title:
- -
- Author(s):
- -
- 关键词:
- 前蛋白转化酶枯草溶菌素9 ; 炎性反应; 动脉粥样硬化; 心肌梗死
- Keywords:
- -
- 分类号:
- -
- DOI:
- 10.3969/j.issn.1673-6583.2023.01.002
- 文献标识码:
- -
- 摘要:
- 动脉粥样硬化性心血管疾病（ASCVD）的发生发展与炎性反应密切相关。前 蛋白转化酶枯草溶菌素9（PCSK9）通过脂质依赖途径或非脂质依赖途径参与对炎性反应 的调节。该文介绍PCSK9 对ASCVD 炎性反应的调控机制及对炎性反应相关细胞的影响。
- Abstract:
- -
参考文献/References
[1] Ding ZF, Pothineni NVK, Goel A, et al. PCSK9 and
inflammation: role of shear stress, pro-inflammatory cytokines,and LOX-1[J]. Cardiovasc Res, 2020, 116(5):908-915.
[2] Patoulias D, Stavropoulos K, Imprialos K, et al. Inflammatory
markers in cardiovascular disease; lessons learned and future
perspectives[J]. Curr Vasc Pharmacol, 2021, 19(3):323-342.
[3] Everett BM, MacFadyen JG, Thuren T, et al. Inhibition
of interleukin-1β and reduction in atherothrombotic
cardiovascular events in the CANTOS trial[J]. J Am Coll
Cardiol, 2020, 76(14):1660-1670.
[4] Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in
patients with chronic coronary disease[J]. N Engl J Med, 2020,
383(19):1838-1847.
[5] Ragusa R, Basta G, Neglia D, et al. PCSK9 and
atherosclerosis: looking beyond LDL regulation[J]. Eur J Clin
Invest, 2021, 51(4):e13459.
[6] Qi ZY, Hu L, Zhang JJ, et al. PCSK9 (proprotein convertase
subtilisin/kexin 9) enhances platelet activation, thrombosis,
and myocardial infarct expansion by binding to platelet
CD36[J]. Circulation, 2021, 143(1):45-61.
[7] Patriki D, Saravi SSS, Camici GG, et al. PCSK 9: a link
between inflammation and atherosclerosis[J]. Curr Med Chem,
2022, 29(2):251-267.
[8] Cheng JM, Oemrawsingh RM, Garcia-Garcia HM, et al.
PCSK9 in relation to coronary plaque inflammation: results of
the ATHEROREMO-IVUS study[J]. Atherosclerosis, 2016,
248:117-122.
[9] Kühnast S, van der Hoorn JWA, Pieterman EJ, et al.
Alirocumab inhibits atherosclerosis, improves the plaque
morphology, and enhances the effects of a statin[J]. J Lipid
Res, 2014, 55(10):2103-2112.
[10] Landlinger C, Pouwer MG, Juno C, et al. The AT04A vaccine
against proprotein convertase subtilisin/kexin type 9 reduces
total cholesterol, vascular inflammation, and atherosclerosis
in APOE*3Leiden.CETP mice[J]. Eur Heart J, 2017,
38(32):2499-2507.
[11] Magnasco L, Sepulcri C, Antonello RM, et al. The role of
PCSK9 in infectious diseases[J]. Curr Med Chem, 2022,
29(6):1000-1015.
[12] Cammisotto V, Baratta F, Simeone PG, et al. Proprotein
convertase subtilisin kexin type 9 (PCSK9) beyond lipids:
the role in oxidative stress and thrombosis[J]. Antioxidants
(Basel), 2022, 11(3):569.
[13] Wang XW, Li X, Liu SJ, et al. PCSK9 regulates pyroptosis via
mtDNA damage in chronic myocardial ischemia[J]. Basic Res
Cardiol, 2020, 115(6):66.
[14] Punch E, Klein J, Diaba-Nuhoho P, et al. Effects of
PCSK9 targeting: alleviating oxidation, inflammation, and
atherosclerosis[J]. J Am Heart Assoc, 2022, 11(3):e023328.
[15] Palee S, McSweeney CM, Maneechote C, et al. PCSK9
inhibitor improves cardiac function and reduces infarct size in
rats with ischaemia/reperfusion injury: benefits beyond lipidlowering
effects[J]. J Cell Mol Med, 2019, 23(11):7310-7319.
[16] Da Dalt L, Castiglioni L, Baragetti A, et al. PCSK9 deficiency
rewires heart metabolism and drives heart failure with
preserved ejection fraction[J]. Eur Heart J, 2021, 42(32):3078-
3090.
[17] Dozio E, Ruscica M, Vianello E, et al. PCSK9 expression
in epicardial adipose tissue: molecular association with
local tissue inflammation[J]. Mediators Inflamm, 2020,
2020:1348913.
[18] Sun H, Krauss RM, Chang JT, et al. PCSK9 deficiency reduces
atherosclerosis, apolipoprotein B secretion, and endothelial
dysfunction[J]. J Lipid Res, 2018, 59(2):207-223.
[19] Ferri N, Marchianò S, Tibolla G, et al. PCSK9 knock-out
mice are protected from neointimal formation in response
to perivascular carotid collar placement[J]. Atherosclerosis,
2016, 253:214-224.
[20] Grune J, Meyborg H, Bezhaeva T, et al. PCSK9 regulates the
chemokine receptor CCR2 on monocytes[J]. Biochem Biophys
Res Commun, 2017:312-318.
[21] Wu NQ, Shi HW, Li JJ. Proprotein convertase subtilisin/
kexin type 9 and inflammation: an updated review[J]. Front
Cardiovasc Med, 2022, 9:763516.
[22] Ding ZF, Wang XW, Liu SJ, et al. PCSK9 expression in the
ischaemic heart and its relationship to infarct size, cardiac
function, and development of autophagy[J]. Cardiovasc Res,
2018, 114(13):1738-1751.
[23] Yang CL, Zeng YD, Hu ZX, et al. PCSK9 promotes the
secretion of pro-inflammatory cytokines by macrophages to
aggravate H/R-induced cardiomyocyte injury via activating
NF-κB signalling[J]. Gen Physiol Biophys, 2020, 39(2):123-
134.
[24] Puteri MU, Azmi NU, Kato M, et al. PCSK9 promotes
cardiovascular diseases: recent evidence about its association
with platelet activation-induced myocardial infarction[J]. Life
(Basel), 2022, 12(2):190.
[25] Ricci C, Ruscica M, Camera M, et al. PCSK9 induces a proinflammatory
response in macrophages[J]. Sci Rep, 2018,
8(1):2267.
[26] Badimon L, Luquero A, Crespo J, et al. PCSK9 and LRP5
in macrophage lipid internalization and inflammation[J].
Cardiovasc Res, 2021, 117(9):2054-2068.
[27] Liu A, Frosteg?rd J. PCSK9 plays a novel immunological
role in oxidized LDL-induced dendritic cell maturation and
activation of T cells from human blood and atherosclerotic
plaque[J]. J Intern Med, 2018, 284(2):193-210.
[28] O'Donoghue M, Giugliano R, Keech A, et al. Lipoprotein(a),
PCSK9 inhibition and cardiovascular risk: insights from the
fourier trial[J]. Atherosclerosis, 2018, 275:e9-e10.
[29] Stiekema LCA, Stroes ESG, Verweij SL, et al. Persistent
arterial wall inflammation in patients with elevated
lipoprotein(a) despite strong low-density lipoprotein
cholesterol reduction by proprotein convertase subtilisin/kexin
type 9 antibody treatment[J]. Eur Heart J, 2019, 40(33):2775-
2781.
[30] R?ber L, Ueki Y, Otsuka T, et al. Effect of alirocumab added
to high-intensity statin therapy on coronary atherosclerosis in
patients with acute myocardial infarction: the PACMAN-AMI
randomized clinical trial[J]. JAMA, 2022, 327(18):1771-1781.
备注/Memo
- 备注/Memo:
-
基金项目：国家自然科学基金（81970236）
通信作者：侯磊， E-mail：HL4081@shtrhospital.com
常用功能
统计/Statistics
- 摘要浏览/Viewed1
- 全文下载/Downloads306
- 评论/Comments
